Lumakras 120mg tablet

• Non-small cell lung cancer (NSCLC)
• Colorectal cancer

Lupiparp 100mg Tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine.
Common side effects include:

• Diarrhea
• Nausea
• Vomiting
• Abdominal pain.
• Fatigue
• Muscle/joint pain (myalgia/arthralgia)
• Cough
• Shortness of breath (dyspnea).
• Liver problems (hepatotoxicity)

Contact your healthcare provider if you face any unusual or persistent side effects.

• Take Lumakras 120mg tablet in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results.
• It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.​
  

• Lumakras 120mg tablet is a targeted anticancer medicine with Sotorasib as an active ingredient which is a KRAS G12C inhibitor. This medicine works by binding irreversibly to the abnormal KRAS G12C protein and lock it in an inactive state.
• This action blocks the signaling pathways which provide signals cancer cells to grow and multiply. As a result, it stops the uncontrolled growth of cancer cells.​
  

• Dingemans, A. M. C., Syrigos, K., Livi, L., Paulus, A., Kim, S. W., Chen, Y., ... & Peters, S. (2023). Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT). https://pubmed.ncbi.nlm.nih.gov/40774040/
• Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., ... & Hong, D. S. (2023). Sotorasib in KRAS p. G12C–mutated advanced pancreatic cancer. New England Journal of Medicine, 388(1), 33-43.  https://pubmed.ncbi.nlm.nih.gov/36546651/
• Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., ... & Govindan, R. (2021). Sotorasib for lung cancers with KRAS p. G12C mutation. New England Journal of Medicine, 384(25), 2371-2381. https://pubmed.ncbi.nlm.nih.gov/34096690/
• De Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A. M. C., Mountzios, G., Pless, M., ... & Paz-Ares, L. (2023). Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. The Lancet, 401(10378), 733-746.
• Nakajima, E. C., Drezner, N., Li, X., Mishra-Kalyani, P. S., Liu, Y., Zhao, H., ... & Singh, H. (2022). FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clinical Cancer Research, 28(8), 1482-1486.